Cerus Corp. (NASDAQ:CERS) saw unusually-strong trading volume on Friday . Approximately 2,597,233 shares traded hands during mid-day trading, an increase of 124% from the previous session’s volume of 1,161,189 shares.The stock last traded at $7.37 and had previously closed at $6.97.

A number of equities research analysts recently issued reports on CERS shares. BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Cerus Corp. in a research report on Monday, June 20th. FBR & Co reissued a “buy” rating on shares of Cerus Corp. in a research note on Monday, May 23rd. Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 target price on shares of Cerus Corp. in a research note on Thursday, July 7th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $9.00 target price on shares of Cerus Corp. in a research note on Wednesday, June 22nd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $8.90.

The company’s market cap is $751.64 million. The stock’s 50-day moving average price is $6.30 and its 200 day moving average price is $5.84.

Cerus Corp. (NASDAQ:CERS) last issued its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.01. The firm had revenue of $7.60 million for the quarter, compared to analysts’ expectations of $8.29 million. During the same period last year, the firm posted ($0.17) earnings per share. Cerus Corp.’s revenue for the quarter was down 1.3% on a year-over-year basis. Equities analysts anticipate that Cerus Corp. will post ($0.65) EPS for the current fiscal year.

Several large investors have modified their holdings of CERS. Wells Fargo & Company MN increased its stake in shares of Cerus Corp. by 25.9% in the fourth quarter. Wells Fargo & Company MN now owns 4,901,666 shares of the company’s stock worth $30,979,000 after buying an additional 1,007,430 shares during the last quarter. Stephens Inc. AR increased its stake in shares of Cerus Corp. by 11.3% in the fourth quarter. Stephens Inc. AR now owns 1,112,665 shares of the company’s stock worth $7,032,000 after buying an additional 113,238 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Cerus Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 176,709 shares of the company’s stock worth $1,117,000 after buying an additional 3,126 shares during the last quarter. Finally, Rail Splitter Capital Management LLC increased its stake in shares of Cerus Corp. by 19.0% in the fourth quarter. Rail Splitter Capital Management LLC now owns 832,722 shares of the company’s stock worth $5,263,000 after buying an additional 132,970 shares during the last quarter.

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.